Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the publication of results from C-SURFER,
the first Phase 31 clinical trial to investigate an all-oral,
ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in
treatment-nave and treatment-experienced patients with advanced chronic
kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1)
infection.
Language:
English
Contact:
MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more